Neon Therapeutics, Inc. reported consolidated financial results for the fourth quarter and twelve months of 2018. For the quarter, the company reported net loss was $23,123,000 or $0.84 per basic share as compared to a net loss attributable to common stockholders of $14,476,000 million or $8.93 per basic share a year ago. Loss from operations were $23,774,000 compared to loss from operations of $14,633,000 same period last year. For the twelve months, net loss was $76,934,000 or $5.54 per basic share as compared to a net loss of $47,536,000 for the same period last year or $34.32 per basic share. Loss from operations were $78,701,000 compared to loss from operations of $48,087,000 same period last year.